Paper Retractions Unveil China Academic Fake Review Scams
This article was originally published in PharmAsia News
Out of 43 papers retracted by BioMed Central due to an inappropriate and manipulative peer review process, 41 are from China, involving 38 top hospitals around the country. Some of the affected research papers relate to drugs, including an anti-platelet agent and a novel compound for hepatocellular carcinoma.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
As China is poised to supply medical products to fight the coronavirus around the world, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.